Compare FF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | TNXP |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 198.6M |
| IPO Year | 2005 | 2008 |
| Metric | FF | TNXP |
|---|---|---|
| Price | $4.11 | $13.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 376.0K | ★ 378.8K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $3.09 | $11.60 |
| 52 Week High | $5.12 | $69.65 |
| Indicator | FF | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 41.15 | 48.02 |
| Support Level | $3.78 | $11.93 |
| Resistance Level | $4.13 | $14.52 |
| Average True Range (ATR) | 0.24 | 0.83 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 4.19 | 40.41 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.